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The chromosome band 11q23 is a common target region of chromosomal translocation in different types of leukemia, including 
infantile leukemia and therapy-related leukemia. The target gene at 11q23, MLL, is disrupted by the translocation and becomes 
fused to various translocation partners. We report a case of AML with a rare 3-way translocation involving chromosomes 1, 9, and 
11: t(1;9;11)(p34.2;p22;q23). A 3-yr-old Korean girl presented with a 5-day history of fever. A diagnosis of AML was made on the ba-
sis of the morphological evaluation and immunophenotyping of bone marrow specimens. Flow cytometric immunophenotyping 
showed blasts positive for myeloid lineage markers and aberrant CD19 expression. Karyotypic analysis showed 46,XX,t(1;9;11)
(p34.2;p22;q23) in 19 of the 20 cells analyzed. This abnormality was involved in MLL/MLLT3 rearrangement, which was confirmed 
by qualitative multiplex reverse transcription-PCR and interphase FISH. She achieved morphological and cytogenetic remission af-
ter 1 month of chemotherapy and remained event-free for 6 months. Four cases of t(1;9;11)(v;p22;q23) have been reported previ-
ously in a series that included cases with other 11q23 abnormalities, making it difficult to determine the distinctive clinical features 
associated with this abnormality. To our knowledge, this is the first description of t(1;9;11) with clinical and laboratory data, includ-
ing the data for the involved genes, MLL/MLLT3.
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Chromosomal 11q23 aberrations are frequently observed 
in infantile as well as therapy-related leukemias [1, 2]. The 
target gene at 11q23, MLL, is disrupted by the translocation 
and becomes fused to various translocation partner genes, 
which encode leukemia-specific chimeric proteins. Among 
cases involving 11q23 as an acquired abnormality in hema-
topoietic malignancies, the translocation between 9p22 and 
11q23, t(9;11), is the second-most common translocation, 
and it usually occurs in French-American-British (FAB) 
types with a substantial monocytic element (M4 and M5, 
but particularly M5a) [1, 3]. The associated gene on 9p22 is 
known as MLLT3 and is predicted to encode a 63-kDa pro-
tein, which is a transcription activator [2]. The prognosis of 
patients with MLL/MLLT3 may not be as poor as in other 
MLL leukemias in de novo cases, but it is very poor in cases 
of secondary AML.
In particular, a complex 3-way translocation, t(9;11;v), 
involving a variable third chromosome has been described 
in many cases. However, the involvement of chromosome 1 
is rare. Four cases with t(1;9;11)(v;p22;q23) have been re-
ported in a series that included cases with other abnormali-
ties of 11q23, making it difficult to determine the distinctive 
clinical features associated with this abnormality [3-5]. Here, 
we report a case of AML with t(1;9;11).
A 3-yr-old girl presented with a 5-day history of fever. On 
physical examination, it was found that she had anemic 
conjunctiva without organomegaly. Initial laboratory evalu-
ation of peripheral blood revealed leukocytosis, anemia and 
thrombocytopenia: a white blood cell (WBC) count of 
76.54×10
9/L with 86% abnormal myeloid cells, hemoglobin 
level of 5.6 g/dL, and a platelet count of 22×10
9/L.128     www.kjlm.org
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Bone marrow and peripheral blood smears were stained 
with Wright-Giemsa stain. The bone marrow specimens 
were immunophenotyped using a Cytomics FC 500 with 
CXP software (Beckman Coulter, Fullerton, CA, USA). Bone 
marrow biopsy revealed markedly hypercellular marrow 
with infiltration of leukemic blasts. In the bone marrow as-
pirate, 85.6% of nucleated cells were blasts, which were small- 
to medium-sized cells with coarse nuclear chromatin, dis-
tinct nucleoli, and basophilic cytoplasm (Fig. 1). In flow cy-
tometric immunophenotyping, the population of blasts was 
positive for CD13, CD19, CD33, CD34, CD117, and MPO 
but negative for CD2, CD3, CD5, CD7, CD10, CD14, CD20, 
CD22, and CD56. Therefore, a diagnosis of AML with aber-
rant CD19 expression was made. The patient did not show 
central nervous system (CNS) involvement.
Cytogenetic and FISH analyses were performed on un-
stimulated 24-hr and 48-hr cultures of bone marrow cells 
according to standard techniques. The G-banded metapha-
ses were prepared with trypsin/Wright stain. For qualitative 
multiplex reverse transcription-PCR (RT-PCR), RNA was 
extracted from bone marrow specimens with an RNeasy 
Mini Kit (Qiagen Inc., Valencia, CA, USA) according to the 
manufacturer’s protocol. The multiplex gene rearrangement 
test was performed using a Hemavision
TM kit (Bio-Rad Lab-
oratories, Hercules, CA, USA) to detect 28 types of fusion 
transcripts. Karyotypic analysis showed a karyotype of 46, 
XX,t(1;9;11)(p34.2;p22;q23) in 19 of the 20 cells analyzed: 
46,XX,t(1;9;11)(p34.2;p22;q23)[19]/46,XX[1] (Fig. 2). Us-
ing qualitative multiplex RT-PCR, we found that this abnor-
mal karyotypic clone had an MLL/MLLT3 rearrangement. 
This rearrangement was confirmed by interphase FISH us-
ing the LSI MLL Dual-Color, Break Apart Rearrangement 
Probe (Abbott Molecular, Des Plaines, IL, USA). Cells with 
MLL rearrangement comprised 92% of the 200 cells observ  ed 
at diagnosis.
Fig. 1. Morphology of leukemic cells at diagnosis. In bone marrow aspirate, 
85.6% of nucleated cells were blasts, which were small- to medium-sized 
cells with coarse nuclear chromatin, distinct nucleoli, and small amounts of 
basophilic cytoplasm.
Table 1. Summary of cases with t(1;9;11)(v;p22;q23) reported in the literature
Case No. Sex/age 
(yr) Diagnosis Karyotype MLL gene 
rearrangement Clinical course References
1 F/1 AML M5b 46,XX,t(1;9;11)(q23;p21;q23) Unknown Died 1 month after diagnosis Köller et al. (1989) [4]
2 F/0.5 ALL 46,XX,t(1;9;11)(q25;p21;q23) Positive EFS 3.6 months, now in second remission Swansbury et al. (1998) [3]
3 F/34 AML M0 46,XX,t(1;9;11)(q31;p21-23;q23-24)[21]/46,XX[2] Unknown EFS 94 months Roumier et al. (2003) [5]
4 F/34 AML M0 46,XX,t(1;9;11)(q31;p21;q23) Positive EFS 44.6 months Swansbury et al. (1998) [3]
Abbreviation: EFS, event-free survival.
Fig. 2. G-banded bone marrow karyogram at diagnosis showing 46,XX,t(1; 
9;11)(p34.2;p22;q23).
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The patient received induction chemotherapy with cyta-
rabine, daunorubicin, and etoposide, which was followed 
by consolidation chemotherapy. At the end of the first induc-
tion chemotherapy, bone marrow examination and cytoge-
netic analysis demonstrated no evidence of leukemic blasts 
or abnormal karyotypic clones, but FISH analysis showed 
that 11% of the leukemic clones had persisted. A follow-up 
FISH study at 2 months after diagnosis showed that MLL 
rearrangement was not present. After the first remission, she 
remained event-free for 6 months.
The study of a large series of patients with 11q23 rearran-
gement showed that patients with 11q23 rearrangement 
should not be homogeneous [3-6]. The partner chromo-
some, age, diagnosis, WBC, CNS involvement, and the pres-
ence of other karyotypic abnormalities had significant ef-
fects on the clinical presentation and treatment outcome [3, 
6]. In particular, t(9;11)(p22;q23) has a better prognosis than 
translocations between 11q23 and other chromosomes. Cases 
of complex three-way translocations including chromosome 
1, such as t(1;9;11), are rare and their prognostic significance 
is unclear.
There are 4 case reports regarding t(1;9;11)(v;p21-22;q23) 
in the literature; these reports describe the findings for an 
infant with AML M5b, an infant with ALL, and 2 female 
adults with AML M0 (Table 1) [3-5]. They have been inclu-
ded in a series of cases showing 11q23 abnormality with dif-
ferent partner chromosomes, making it difficult to determine 
the distinctive clinical features associated with t(1;9;11). In 
these previous studies, the patients did not have any addi-
tional chromosomal abnormalities except t(1;9;11). Despite 
their shared cytogenetic abnormalities, there were differen-
ces in morphological diagnosis and clinical progress. These 
clinical differences may appear to reflect the age at diagno-
sis, i.e., one infant died 1 month after diagnosis and the other 
had an event-free survival of 3.6 months in second remis-
sion, but the 2 adults had relatively long event-free survivals 
(44.6 and 94 months). In our patient, a 3-yr-old girl with a 
diagnosis of AML M1, cytogenetic study also indicated 
t(1;9;11) as the sole abnormality. She achieved morphologi-
cal and cytogenetic remission after 1 month of chemother-
apy and was event-free for 6 months. Taken together, these 
observations suggested that patients with t(1;9;11) in de novo 
leukemia have different clinical courses depending on age. 
The prognosis of patients with the t(1;9;11) MLL/MLLT3 
variant may not be as poor as that of other child or adult 
MLL leukemia cases, but it is very poor in cases of infants. 
However, it is possible that there are other causes such as 
unknown involved gene(s) on chromosome 1, CNS involve-
ment, and treatment protocol, but we cannot find any desc-
ription in their literatures [3-5]. Further studies are needed.
Here, we report a case of AML with t(1;9;11). To our know-
ledge, this is the first description of t(1;9;11) with clinical 
and laboratory characteristics, including detection of the 
involved genes, MLL/MLLT3.
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